-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Dyne Therapeutics, Maintains $38 Price Target

Benzinga·12/09/2025 13:23:26
語音播報
Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and maintains $38 price target.